Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
| ▸ | NPY2R | P49146 | 3/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 11/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880877 | 0.93 | BACE1 (0.59) | NPY4RNPY1RNPY2RKISS1RTFPI | |
| SCHEMBL30607418 | 0.92 | BACE1 (0.60) | NPY4RNPY1RNPY2RKISS1RTFPI | |
| SCHEMBL30924727 | 0.91 | TFPI (0.54) | NPY4RNPY1RNPY2RKISS1RTFPI | |
| SCHEMBL29730544 | 0.86 | NPY4R (0.58) | NPY4RNPY1RNPY2RKISS1RBACE1 | |
| SCHEMBL30512630 | 0.86 | NPY4R (0.63) | NPY4RNPY1RNPY2RTFPINPY5R | |
| SCHEMBL31353030 | 0.85 | NPY4R (0.57) | NPY4RNPY1RNPY2RKISS1RTFPI | |
| SCHEMBL31558556 | 0.85 | BACE1 (0.57) | TFPIBACE1BACE2OPRD1 | |
| SCHEMBL30924748 | 0.85 | TFPI (0.52) | NPY4RNPY1RNPY2RKISS1RTFPI | |
| SCHEMBL30865077 | 0.85 | NPY1R (0.55) | NPY4RNPY1RNPY2RKISS1RBACE1 | |
| SCHEMBL29950752 | 0.85 | NPY1R (0.55) | NPY4RNPY1RNPY2RKISS1RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746467-B1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2025-10-08 | — | — | EP | disclosed |
| CN-111770934-B | Modified lipidated relaxin B chain peptides and therapeutic uses thereof | 赛诺菲 | 2024-10-18 | — | — | CN | disclosed |
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | NPY4R 48/4885NPY1R 34/4885NPY2R 54/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | NPY4R 39/4885NPY1R 16/4885NPY2R 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.